Ascendis Pharma AS (ASND) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

ASND

128.13

USD-3.74-2.84%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Filings

News

Chart

Latest News

@MarketRebels

Sep 16, 2024

STARTS NOW Rebel's Edge 🏴‍☠️ 1pm CME Fed Tool swings to 61% Chance of 50 bps cut. China's economy showing signs of strain. #UOA in $ORCL $AAPL $ASND $NUVL with @MXLESQ Sports 🏈 @petenajarian NFL: Early poor start for great teamsRavens 0-2, Cinci 0-2... why? https://t.co/qlnNHGky8b

Seeking Alpha

3 years

ASND, GDS, ADSK and CDZI among after hours movers

Analysts Recommendations

Bullish

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

127.75USD

133.38USD

52 Week Range

111.09USD

161.00USD

Market Cap

8.07BUSD

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

US04351P1012

CUSIP

04351P101

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

-2.57

Dividend Share

Dividend Yield

Earnings Share

-7.67

Wall Street Target Price

192.6638

EPS Estimate Current Year

-6.9247

EPS Estimate Next Year

-3.6721

EPS Estimate Current Quarter

-1.5153

EPS Estimate Next Quarter

-1.4377

Most Recent Quarter

Profitability

Revenue TTM

317,628,000

Gross Profit TTM

271,750,016

EBITDA

-347,192,992

Profit Margin

-154.12%

Return On Assets TTM

-27.92%

Return On Equity TTM

-818.43%

Revenue Per Share TTM

5.595

Qtly Revenue Growth YOY

-24.00%

Diluted Eps TTM

-7.67

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

24.7834

Price Book MRQ

14.5547

Enterprise Value Revenue

Enterprise Value EBITDA

-20

Peers analysis

VRTXVertex Pharmaceuticals Inc
422.00
1.17%
CSLLYCSL Ltd
86.16
0.51%
BNTXBioNTech SE
113.00
0.32%
UCBJFUCB SA
192.00
0.00%
UCBJYUCB SA ADR
93.50
-5.11%

CMXHFCSL Limited
163.15
-2.37%
ARGXargenx NV ADR
644.99
-2.24%
ALNYAlnylam Pharmaceuticals Inc
244.79
-1.80%
ARGNFargenx SE
620.25
-1.77%
REGNRegeneron Pharmaceuticals Inc
682.00
-1.64%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2025